Barry Simon
Director/Board Member chez VIRACTA THERAPEUTICS, INC.
Fortune : 17 M $ au 31/03/2024
Profil
Barry J. Simon occupe le poste de président du conseil d'administration, président et chef de la direction de Brink Biologics, Inc. et celui de directeur et chef des affaires générales de ImmunityBio, Inc. Il est également membre du conseil d'administration de Cue Biopharma, Inc. (ancien président) et de Viracta Therapeutics, Inc. Dans le passé, le Dr Simon a occupé le poste de vice-président de Roche Holding AG et de vice-président de Roche Diagnostics Corp. (filiale de Roche Holding AG), vice-président de HealthPro BioVentures LLC, vice-président de North Sound Capital LLC, vice-président des affaires cliniques et réglementaires d'iTherX Pharmaceuticals, Inc. et président, directeur et directeur administratif de NantKwest, Inc. et vice-président d'Immunomedics, Inc. Le Dr Simon a obtenu un doctorat de l'Université d'État de New York au Downstate Medical Center.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNITYBIO INC
0,46% | 22/02/2024 | 3 123 761 ( 0,46% ) | 17 M $ | 31/03/2024 |
| 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Barry Simon
| Sociétés | Poste | Début |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | 03/03/2021 |
| IMMUNITYBIO, INC. | Director/Board Member | 01/01/2007 |
| Brink Biologics, Inc. | Chief Executive Officer | 01/03/2015 |
Anciens postes connus de Barry Simon
| Sociétés | Poste | Fin |
|---|---|---|
| CUE BIOPHARMA, INC. | Chairman | - |
| IMMUNITYBIO, INC. | Chief Executive Officer | 01/03/2015 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Director/Board Member | 01/11/2020 |
Roche Diagnostics Corp.
 Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Corporate Officer/Principal | 01/12/2004 |
| Roche Labs | Corporate Officer/Principal | - |
Formation de Barry Simon
| State University of New York at Downstate Medical Center | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| IMMUNITYBIO, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | Distribution Services |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology NantKwest, Inc. engages in the research and development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA. | Health Technology |
Roche Diagnostics Corp.
Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Health Technology |
HealthPro BioVentures LLC
 HealthPro BioVentures LLC Investment ManagersFinance Founded in 2003, HealthPro BioVentures LLC is a life sciences investment bank and strategic advisory firm headquartered in New York City | Finance |
North Sound Capital LLC
 North Sound Capital LLC Investment ManagersFinance North Sound Capital LLC (North Sound) is an independent hedge fund management firm headquartered in Greenwich, Connecticut. The firm was founded by Tom McAuley in 2001. North Sound provides investment advice to private investment vehicles offered to high net worth investors. | Finance |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
| Brink Biologics, Inc. | |
| Roche Labs |
